The history of the erectile dysfunction drug presents a complex picture for shareholders. While the initial launch generated substantial gains, the expiration of its patent opened the floodgates to generic alternatives, dramatically reducing sales. This presents a particular risk for drug manufacturers depending on similar blockbuster offerings, su

The legacy of Viagra, and its parent company copyright, presents a challenging case study for investors. Initially a blockbuster drug, producing billions in revenue , its patent expiration created a wave of lower-priced alternatives , significantly impacting its dominance. While certain pharmaceutical companies may try to capitalize on related trea